Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development
January 26 2021 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced the
appointment of Brendan Luu as Senior Vice President, Business
Development and member of the company’s senior management team. Mr.
Luu brings more than 20 years of diversified business development
and sales and marketing experience in the pharmaceutical and
technology fields to Enanta, spanning a broad range of therapeutic
areas, asset stages and deal structures.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210126005236/en/
Brendan Luu, Senior Vice President,
Business Development, Enanta Pharmaceuticals (Photo: Business
Wire)
“It is an ideal time to welcome Brendan to the Enanta team,
particularly as we prepare for a catalyst-rich year, including data
readouts, in our wholly owned pipeline of virology and liver
disease treatment candidates,” said Jay R. Luly, Ph.D., President
and Chief Executive Officer. “In the coming year and continuing
through the advancement of our clinical and preclinical programs,
Brendan’s insights and experience leading business development
growth strategies will be tremendous assets to Enanta.”
“Enanta is an established leader in the discovery and
development of virology and liver disease treatments. The company’s
product candidates for respiratory syncytial virus, hepatitis B
virus and non-alcoholic steatohepatitis have transformative
potential for the treatment of patients in these significant
disease populations, and Enanta’s discovery efforts in human
metapneumovirus and SARS-CoV-2 are equally promising,” said Brendan
Luu. “I am eager to collaborate with the company’s seasoned
leadership team to continue their proven legacy of success and
bring meaningful treatments to patients in need.”
Mr. Luu joins Enanta following 17 years at Merck KGaA, where he
held roles of increasing responsibility. Most recently, he was Vice
President and Global Head of Oncology Business Development,
responsible for setting the franchise business development strategy
and was accountable for its execution, including the completion of
several major transactions across all stages of drug development in
line with the company’s R&D goals. Prior to assuming the role
in 2018, Mr. Luu was Senior Director and Global Head of Business
Development, Strategic Initiatives, where he led the strategy and
partnering efforts to secure external financing for Merck KGaA’s
late-stage pipeline. Before that, Mr. Luu was Director, Global
Licensing and Business Development, Neurology and Immunology, where
he led in/out licensing transactions for preclinical and
clinical-stage assets to support R&D in neurodegenerative
diseases. Previously, he was an Associate Director of Regional
Business Development, General Medicines responsible for growing the
product portfolio in the Asia-Pacific region. Earlier in his
career, he held various roles in the chemicals industry with BASF
Corporation and in telecommunications with Tyco International,
working in engineering, sales and marketing.
Mr. Luu graduated magna cum laude from Drexel University with a
B.S. in Chemical Engineering and Biology. He also holds an M.B.A.
from the New York University Stern School of Business.
About Enanta Pharmaceuticals, Inc. Enanta is using its
robust, chemistry-driven approach and drug discovery capabilities
to become a leader in the discovery and development of small
molecule drugs for the treatment of viral infections and liver
diseases. Enanta’s research and development efforts have produced
clinical candidates for the following disease targets: respiratory
syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic
steatohepatitis (NASH). Enanta is also conducting research in human
metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
FORWARD LOOKING STATEMENTS This press release contains
forward-looking statements, including statements with respect to
the prospects for advancement of Enanta’s clinical development
programs. Statements that are not historical facts are based on
management’s current expectations, estimates, forecasts and
projections about Enanta’s business and the industry in which it
operates and management’s beliefs and assumptions. The statements
contained in this release are not guarantees of future performance
and involve certain risks, uncertainties and assumptions, which are
difficult to predict. Therefore, actual outcomes and results may
differ materially from what is expressed in such forward-looking
statements. Important factors and risks that may affect actual
results include: the discovery and development risks of Enanta’s
programs in RSV, NASH, HBV, hMPV and SARS-CoV-2; the competitive
impact of development, regulatory and marketing efforts of others
in those disease areas; any continuing impact of the COVID-19
pandemic on Enanta’s business operations and clinical trials;
Enanta’s lack of clinical development experience; Enanta’s need to
attract and retain senior management and key research and
development personnel; Enanta’s need to obtain and maintain patent
protection for its product candidates and avoid potential
infringement of the intellectual property rights of others; and
other risk factors described or referred to in “Risk Factors” in
Enanta’s most recent Form 10-K for the fiscal year ended September
30, 2020, and other periodic reports filed more recently with the
Securities and Exchange Commission. Enanta cautions investors not
to place undue reliance on the forward-looking statements contained
in this release. These statements speak only as of the date of this
release, and Enanta undertakes no obligation to update or revise
these statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210126005236/en/
Investor and Media Contact: Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024